These inhibitors have been shown to be effective in “flipping the switch” in many patients with PD-1+ and programmed-death ligand 1+ (PD-L1+) cancers[139] with potential for therapeutic use in patients with metastatic sarcoma[140], Hodgkin’s lymphoma[141], and gastroesophageal cancer[142]. This evidence concerns the gene CD274 and cancer.